The nasal spray Neffy is the first non-injectable epinephrine to treat the life-threatening allergic response ARS Pharmaceuticals, Inc. The first-ever needle-free alternative to the EpiPen and similar ...

ARS Pharma had high hopes that the FDA on Tuesday would approve its flagship product, a needle-free treatment for adults and children with severe allergic reactions. But instead, the drugmaker was set ...

The Food and Drug Administration has approved ARS Pharmaceuticals’ nasal spray as the first needle-free emergency treatment for potentially fatal allergic reactions, the agency said on Friday. The ...

SAN DIEGO, July 18, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect ...

ALK (ALKB:DC / OMX: ALK B) today announced that the Committee for Medicinal Products for Human Use (‘CHMP’) of the European Medicines Agency has adopted a positive opinion recommending the granting of ...

FDA advisors recommended that the agency approve an intranasal epinephrine product for type I allergic reactions, including anaphylaxis, despite concerns about the lack of clinical efficacy data. On ...

Anaphylaxis (or "anaphylactic shock") is a life-threatening allergic reaction that needs to be treated right away. If you have an anaphylactic reaction, you need a dose of epinephrine (adrenaline) as ...

Anaphylaxis is a severe allergic reaction that can quickly become life threatening. It can affect breathing, digestion, and circulation within seconds of exposure. Symptoms can include wheezing, chest ...

Biphasic anaphylaxis is a second anaphylactic reaction after successful treatment, without new allergen exposure. It can occur up to 72 hours later, often peaking within 8 to 11 hours. Symptoms can ...

Anaphylaxis can cause severe itching, difficulty breathing, fainting, and abdominal pain. These symptoms usually begin about 30 minutes after coming into contact with an allergy trigger. First, call ...

EURneffy ® 2 mg nasal spray offers a simple-to-use, 3,4 pocket-sized alternative to traditional AAIs, with the potential to transform the lives of those with severe allergies in the UK. It is designed ...